You are not logged in.

Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours

Khasraw, M., Townsend, A., Price, T., Hart, J., Bell, D. and Pavlakis, N. 2010, Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours, Internal medicine journal, vol. 40, no. 6, pp. 453-458, doi: 10.1111/j.1445-5994.2010.02245.x.

Attached Files
Name Description MIMEType Size Downloads

Title Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours
Author(s) Khasraw, M.
Townsend, A.
Price, T.
Hart, J.
Bell, D.
Pavlakis, N.
Journal name Internal medicine journal
Volume number 40
Issue number 6
Start page 453
End page 458
Total pages 6
Publisher Wiley-Blackwell Publishing Asia
Place of publication Richmond, Vic.
Publication date 2010-06
ISSN 1444-0903
1445-5994
Keyword(s) neuroendocrine tumour
objective response
Sandostatin
somatostatin analogue
Summary Conventional cytotoxic chemotherapy is not usually effective in neuroendocrine tumours (NET). Somatostatin analogues (SSA) such as octreotide (Sandostatin; octreotide LAR and lanreotide) are typically used to treat symptoms caused by NET, but not as the primary treatment aiming for an objective response. Recently, results from the PROMID (Placebo-controlled prospective Randomized study on the antiproliferative efficacy of Octreotide LAR in patients with metastatic neuroendocrine MIDgut tumours) trial were published showing that octreotide LAR significantly lengthens the time to tumour progression compared with a placebo in patients with functionally active and inactive metastatic midgut NET. We report a retrospective descriptive analysis of six patients, treated at two Australian institutions, who obtained an objective radiological tumour response on long acting SSA. In this retrospective series of NET, radiological responses were observed using single agent SSA, which was administered mainly for symptom management. This could be due to an antiproliferative and/or antiangiogenic activity of this agent in NET. A response can occur beyond 12 months, which might explain why the response rate is under reported in NET trials. Further investigation in prospective trials is warranted and the possibility for late responses might have implications for trial design.
Language eng
DOI 10.1111/j.1445-5994.2010.02245.x
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2010, The Authors
Persistent URL http://hdl.handle.net/10536/DRO/DU:30046487

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in TR Web of Science
Scopus Citation Count Cited 4 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 171 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Tue, 31 Jul 2012, 12:24:27 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.